Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse

Endocrinology

Volumn 139, Issue 5, 1998, Pages 2486-2492

  Martel, Céline ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Gauthier, Sylvain ^a   Mérand, Yves ^a   Li, Xun ^a   Provencher, Louis ^a   Candas, Bernard ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; FULVESTRANT; TOREMIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031764761     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.5.5968     Document Type: Article

References (40)

1. McGuire WL, Carbone PP, Seard ME, Esche GC 1975 Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen Receptors in Human Breast Cancer. Raven Press, New York, pp 1-7
2. Furr BJ, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205
3. Wakeling AE, Bowler J 1988 Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141-147
4. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
5. Wakeling AE, Bowler J 1992 ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43:173-177
6. Nique F, Van de Velde P, Brémaud J, Hardy M, Philibert D, Teutsch G 1994 11β-Amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Mol Biol 50:21-29
7. Simard J, Dauvois S, Haagensen DE, Lévesque C, Mérand Y, Labrie F 1990 Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 126:3223-3231
8. Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F 1991 Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 51:3131-3135
9. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F 1991 Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N, n-butyl-N-methyl-11-(16′α-chloro-3′,17β-dihydroxy-estra- 1′,3′,5′-(10′)triene-7′ α-yl)undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51:2797-2802
10. Lévesque C, Mérand Y, Dufour JM, Labrie C, Labrie F 1991 Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34:1624-1630
11. Labrie C, Martel C, Dufour JM, Lévesque C, Mérand Y, Labrie F 1992 Novel compounds inhibit estrogen formation and action. Cancer Res 52:610-615
12. Wakeling AE 1993 The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1-9
13. Gottardis MM, Jiang SY, Jeng MH, Jordan VC 1989 Inhibition of tamoxifenstimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093
14. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Quellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F 1997 (S)-(+)-[4-[7-(2, 2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1- benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J Med Chem 40:2117-2122
15. Luo S, Martel C, Sourla A, Gauthier S, Mérand Y, Bélanger A, Labrie C, Labrie F, Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer, in press
16. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F 1997 Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced prolieration of T-47D, ZR-75-1 and MCF-7 human breasts cancer cells in vitro. Int J Cancer 73:381-391
17. Martel C, Provencher L, Li X, St-Pierre A, Leblanc G, Gauthier S, Mérand Y, Labrie F, Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J Steroid Biochem Mol Biol, in press
18. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perila M, Pippo I, Sundquist H, Sodervall M, Toivola R 1986 A new triphenylethylene compound, FC-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 17:103-108
19. Robinson SP, Jordan VC 1989 Antiestrogenic action of toremifene on hormone-dependent, and heterogeneous breast tumor growth in athymic mouse. Cancer Res 49:1758-1762
20. di Salle E, Zaccheo T, Ornati G 1990 Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 110:203-206
21. Kangas L 1990 Review of the pharmacological properties of toremifene. J Steroid Biochem 36:191-195
22. Iino Y, Takai Y, Ando T, Sugamata N, Maemura M, Takeo T, Ohwada S, Morishita Y 1993 Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice. Cancer Chemother Pharmacol 32:353-358
23. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
24. Asselin J, Kelly PA, Caron MG, Labrie F 1977 Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 101:666-671
25. Asselin J, Labrie F 1978 Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J Steroid Biochem 9:1079-1082
26. Asselin J, Mélançon R, Moachon G, Bélanger A 1980 Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. Cancer Res 40:1612-1622
27. Raynaud JP, Ojasso T, DelaRue JC, Magdelenat H, Martin P, Philibert D 1977 Estrogen and progestin receptors in human breast cancer. In: McGuire WL, Raynaud JP, Baulieu EE (eds) Progesterone Receptors in Normal and Neoplastic Tissues. Raven Press, New York, vol 4:171-191
28. Dukes M, Miller D, Wakeling AE, Waterton JC 1992 Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 135:239-247
29. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blarney RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE 1994 Investigation of a pure antiestrogen ICI182780 in women with primary breast cancer. Cancer Res 54:408-414
30. Howell A, DeFriend D, Robertson J, Blarney R, Walton P 1995 Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345:29-30
31. Jordan VC, Rowsby L, Dix CJ, Prestwich G 1978 Dose-related effects of non-steroidal antioestrogens nad oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J Endocrinol 78:71-81
32. Jordan VC, Dix CJ, Rowsby L, Prestwich G 1977 Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol Cell Endocrinol 7:177-192
33. Robinson SP, Parker CJ, Jordan VC 1990 Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat 16:S9-S17
34. Jordan VC, Robinson SP 1987 Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46:1870-1874
35. Gradishar W, Jordan VC 1997 Clinical potential of new antiestrogens. J Clin Oncol 15:840-852
36. Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS 1991 The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010
37. Parker MG 1993 Action of pure antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131-137
38. McClelland RA, Gee JM, Francis AB, Robertson JF, Blarney RW, Wakeling AE, Nicholson RI 1996 Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-α protein expression in human breast cancer. Eur J Cancer 32a:413-416
39. Labrie F, Pelletier G, Labrie R, Ho-Kim MA, Delgado A, MacIntosh B, Fortier C 1968 Liaison transcortine-corticosterone et contrôle de l'activité hypophysosurrénalienne chez le rat. Ann Endocrinol (Paris) 29:29-44
40. Labrie F, Pelletier G, Raynaud JP, Ducommun P, Belgado A, Macintosh B, Fortier C 1970 Liaison transcortine-corticostéroïdes et interactions entre hypophyse, thyroïde, surrénales et gonades. Med Hyg 28:266-281